We are live on ! Find out more
HBIO icon

Harvard Bioscience

68 hedge funds and large institutions have $66M invested in Harvard Bioscience in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 17

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

9% more capital invested

Capital invested by funds: $60.6M → $66M (+$5.45M)

6.3% more ownership

Funds ownership: 0%6.3% (+6.3%)

1% less funds holding

Funds holding: 6968 (-1)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
68
Holders Change
-1
Holders Change %
-1.45%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
8
Increased
27
Reduced
17
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
76
Deutsche Bank
Germany
+$661 +26 +2,600%

HBIO Hedge Fund Activity: Q4 2016 in Review

68 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2016, worth a combined $66M — up 9% from $60.6M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new HBIO positions and 7 closed out — a net gain of 1 holder — while 27 added to existing stakes and 17 trimmed.

The largest buyer was Glacier Peak Capital, adding an estimated $1.28M. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $2.85M sold.

  • 68 institutional investors held Harvard Bioscience (HBIO) as of Q4 2016, down from 69 in Q3 2016.
  • Funds reported $66M of Harvard Bioscience stock for Q4 2016, up 9% quarter-over-quarter.
  • 8 funds opened new Harvard Bioscience positions in Q4 2016 and 7 closed out, a net change of +1 holder.
  • The largest Harvard Bioscience buyer in Q4 2016 was Glacier Peak Capital, an estimated $1.28M added.
  • The largest Harvard Bioscience seller in Q4 2016 was Polar Asset Management Partners, an estimated $2.85M sold.

Based on aggregated 13F filings for Q4 2016.